How an Aggressive Treatment of No-reflow Phenomenon in Primary Percutaneous Coronary Intervention with High Thrombus Burden can Achieve a Grade III TIMI-flow: A Case Report
Conclusion Aggressive and precise treatment with a drug of choice is required to counteract the no-reflow phenomenon. Presently, only a limited range of first-line medications are available to treat this condition. Not only that, but several of the prescribed medications are not easily accessible, especially in developing countries. Therefore, we offer a novel combination medicaments consisting of nitroglycerin, heparin, and glycoprotein IIb/IIIa inhibitor as an alternative treatment of the no-reflow phenomenon. [...] Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents | Abstract | Full text
Source: International Journal of Angiology - Category: Cardiology Authors: Martha, Januar Wibawa Putra, Iwan Cahyo Santosa Kamarullah, William Husink, Aron Sihite, Teddy Arnold Tags: Case Report Source Type: research
More News: Angiography | Angioplasty | Cardiology | Coronary Angioplasty | Emergency Medicine | Eptifibatide | Heart Attack | Integrilin | Morphine | Nitroglycerin | Pain | Pain Management | Percutaneous Coronary Intervention | Perfusion | Thrombosis